Physician profile

Mark A Hardy

Surgery · New York, NY

NPI 1750465613

$1,731.72

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$66.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Globus Medical, INC. $920.12 2019
Veloxis Pharmaceuticals, INC. $481.61 2019-2021
Csl Behring $118.16 2019
Astellas Pharma Global Development $107.70 2019-2020
Integra Lifesciences Corporation $66.06 2024 Integra, Primatrix, Integra Dermal Regeneration Template
Acell, INC. $22.49 2019
Boehringer Ingelheim Pharmaceuticals, INC. $15.58 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark A Hardy

$1,731.72

in general payments reported 2019-2025

Years
2019-2024
Top company
Globus Medical, INC.

https://glasscript.com/doctor/306210/mark-a-hardy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.